Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CLL patients left in the dark: study maps treatment gaps after key drug fails

NCT ID NCT05621148

Knowledge-focused Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 152 adults with chronic lymphocytic leukemia (CLL) whose cancer stopped responding to a class of drugs called BTK inhibitors (like ibrutinib) and, in some cases, also to venetoclax. The goal was to understand what treatments doctors used next and how well they worked, since there is no standard approach for these patients. The study did not test a new treatment but instead collected real-world data to highlight unmet medical needs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

152 people

The number who actually took part.

Started

Jan 2023

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients previously exposed to ibrutinib (or other BTKi) : treatment with a BTKi in at least one of two or more prior lines of therapy and progressed

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented diagnosis of CLL or small lymphocytic leukemia (SLL). * ≥ 18 years of age the time of initial diagnosis. * Venetoclax therapy in at least third line of treatment (LOT) during the period considered, following at least one LOT with BTKi * Patients who received VEN during prior LOTs are eligible. * Patient not opposed to data collection (including deceased patients) Exclusion Criteria: * Exposure to cellular therapy, including CAR T-cells / Allo-Stem Cell Transplantation. * Richter's transformation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bruton tyrosine kinase inhibitor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bruton tyrosine kinase inhibitor CLL, refractory CLL, relapsed Small lymphocytic leukemia

Contacts and locations

Locations

  • Bordeaux Pessac

    Pessac, 33604, France

  • CHU Estaing - Hématologie Clinique Adulte

    Clermont-Ferrand, 63000, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Léon Bérard - Hématologie

    Lyon, 69373, France

  • Institut Paoli-Calmettes - Hématologie Clinique

    Marseille, 13273, France

  • MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique

    Montpellier, 34295, France

  • Strasbourg - Icans

    Strasbourg, 67033, France

  • Toulouse - IUCT Oncopole - Service d'Hématologie

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.